Pharmaceutical

argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis

The positive opinion relied on a comparator study that showed the subcutaneous version was non-inferior to the intravenous one.

Sep 15, 2023 - 20:00
argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis
The positive opinion relied on a comparator study that showed the subcutaneous version was non-inferior to the intravenous one.
Read the original article

Tags:

Previous Article

Iovance’s PDUFA date for lifileucel pushed due to FDA backlog

Next Article

Signal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Medicxi and Starpharma to develop dendrimer-based cancer treatments

Medicxi and Starpharma to develop dendrimer-based cance...

Apr 9, 2024

Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy

Hemogenyx gets reprieve as FDA lifts clinical hold on A...

Feb 10, 2024

Five ways to build trust in patient data sharing

Five ways to build trust in patient data sharing

Aug 26, 2023